PNT
NASDAQPOINT Biopharma Global Inc.
Latest news
25 items- PRDelcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of DirectorsDelcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
- SECSEC Form 15-12G filed by POINT Biopharma Global Inc.15-12G - POINT Biopharma Global Inc. (0001811764) (Filer)
- SECSEC Form EFFECT filed by POINT Biopharma Global Inc.EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)
- SECSEC Form EFFECT filed by POINT Biopharma Global Inc.EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)
- INSIDERSEC Form 4 filed by Goodman Jonathan R.4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERSEC Form 4 filed by Kelly Justyna4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERMccann Joe A. closing all direct ownership in the company (SEC Form 4)4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERSEC Form 4 filed by Jensen Jessica D.4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERFleshner Neil E. closing all direct ownership in the company (SEC Form 4)4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERHogue Gerald L. closing all direct ownership in the company (SEC Form 4)4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERMalik Rajesh closing all direct ownership in the company (SEC Form 4)4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERLubner David Charles returned 3,600 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERSEC Form 4 filed by Demers William L.4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERSEC Form 4 filed by Silber Allan C4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- INSIDERMargolin Yael returned 1,710 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
- 13D/GSEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
- NEWSRecent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably PositionedWith recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ:FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE:BMY) has agreed to acquire RayzeBio Inc (NASDAQ:RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. On Wednesda
- SECSEC Form POS AM filed by POINT Biopharma Global Inc.POS AM - POINT Biopharma Global Inc. (0001811764) (Filer)
- SECSEC Form POS AM filed by POINT Biopharma Global Inc.POS AM - POINT Biopharma Global Inc. (0001811764) (Filer)
- SECSEC Form S-8 POS filed by POINT Biopharma Global Inc.S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)
- SECSEC Form S-8 POS filed by POINT Biopharma Global Inc.S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)
- SECSEC Form S-8 POS filed by POINT Biopharma Global Inc.S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)
- SECSEC Form 25-NSE filed by POINT Biopharma Global Inc.25-NSE - POINT Biopharma Global Inc. (0001811764) (Subject)
- SECPOINT Biopharma Global Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits8-K - POINT Biopharma Global Inc. (0001811764) (Filer)
- PRLilly Completes Acquisition of POINT BiopharmaINDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ:PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we
PNT FAQ
7 questionsWhat does POINT Biopharma Global Inc. do?
POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product...Where does PNT stock trade?
POINT Biopharma Global Inc. (PNT) is listed on NASDAQ.What sector and industry is PNT in?
POINT Biopharma Global Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did POINT Biopharma Global Inc. go public?
POINT Biopharma Global Inc. (PNT) completed its IPO in 2020.What are analysts saying about PNT?
POINT Biopharma Global Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $1400.00 price target on 2023-07-20. Recent price targets range from $1000.00 to $2200.00.What companies are similar to PNT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PNT side-by-side with any of them on Quantisnow.How can I track PNT on Quantisnow?
Quantisnow aggregates POINT Biopharma Global Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PNT to receive live email and push alerts on every new disclosure.